Health
Combination immunotherapy benefits subset of patients with advanced prostate cancer – Medical Xpress
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic cast…
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), an “immune-cold” cancer that does not typically respond well to immunotherapy.
In a cohort of patients without previous chemotherapy treatment, the overall response rate (ORR) was 25% and median ove…
-
Noosa News8 hours agoFears for the future of retro Chinese dining after blaze guts Sundoo in Townsville
-
Business13 hours agoTop brokers name 3 ASX shares to buy next week 25 May 2025
-
General10 hours agoAustralia’s native flora emerges as an increasingly popular muse for bonsai hobbyists
-
Noosa News23 hours ago‘Stranded’ Eddie the echidna thought to have swum from Bribie Island’s broken tip